Gilbert & Cook Inc. Grows Stock Position in Johnson & Johnson $JNJ

Gilbert & Cook Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 4.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,508 shares of the company’s stock after purchasing an additional 341 shares during the period. Gilbert & Cook Inc.’s holdings in Johnson & Johnson were worth $1,300,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after acquiring an additional 1,170,120 shares during the period. Northern Trust Corp lifted its position in Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after purchasing an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after buying an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after buying an additional 448,666 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $189.02 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company’s fifty day moving average price is $183.28 and its 200-day moving average price is $167.66. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The company has a market capitalization of $455.40 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JNJ shares. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.